|
ASOs which target KCTD20 can help reduce neurodegeneration.
Selective and targeted treatment, offering durable neuroprotection and clearance of toxic proteins.
Can be used to treat neurodegeneration, FTD, ALS with multiple genetic backgrounds.
Abstract
Glutamate excitotoxicity drives neurodegeneration in ALS and FTD, yet current treatments offer...
|